# Infliximab Therapy in Ocular Manifestations of Behcet's Disease

Thesis

Submitted for Partial Fulfillment of M.D. Degree
In
Rheumatology & Rehabilitation

**Presented By** 

**Sherif Ahmed Shawky** 

**SUPERVISORS** 

Prof. Dr. Ayman El-Garf

Professor of Rheumatology & Rehabilitation Faculty of Medicine Cairo University

Prof. Dr. Amira Abd El-Saboor Shahin

Professor of Rheumatology & Rehabilitation
Faculty of Medicine
Cairo University

Faculty of Medicin, Cairo University 2012

#### **Abstract**

**Objective:** This study was designed to assess the efficacy and safety of Infliximab (IFX) in the treatment of ocular manifestations in patients with Behcet's disease, namely BD-associated refractory posterior uveitis (PU) as expressed by VA improvement from baseline and to investigate the efficacy of IFX to reduce disease flare-up, to assess the proportion of relapse free subjects at the end of follow-up, and the percentage of patients achieving a complete or partial remission, and to evaluate the tolerability and safety of the treatment.

Methods: Twenty patients with refractory Behcet uveitis PU (17 males and 3 females) were included in this study. patients were subjected to full history taking, physical examination, purified protein derivative (PPD) test, laboratory tests including erythrocyte sedimentation rate (ESR), Creactive protein (CRP), blood cell count with differential count, renal and liver function, antinuclear antibody titer .Ophthalmologic evaluation consisted of a complete ocular examination including best-corrected VA, slit-lamp biomicroscopy, tonometry and ophthalmoscopy, optical coherence tomography (OCT), & fundus fluorescein angiography (FFA).

**Results:** By the end of week 8 (induction), we observed a highly significant improvement inVA (right eyes:  $0.1\pm0.09$  vs  $0.6\pm0.2$ , P=0.001) (Left eyes:  $0.19\pm0.17$  vs  $0.6\pm0.3$ , P=0.001), and by the end of week 32 there was further improvement in VA, (right eye:  $0.6\pm0.2$  vs  $0.8\pm0.2$ , P=0.001), (left eyes:  $0.6\pm0.3$  vs  $0.8\pm0.2$ , P=0.001), but this improvement was nearly the same by the end of week 58, (right eyes:  $0.8\pm0.2$  vs  $0.8\pm0.2$ ) (left eyes:  $0.8\pm0.2$  vs  $0.8\pm0.2$ ). It was noted that improvement in VA was more evident in group A than in group B (P<0.05). At the end of a follow-up of 12 months, 16/20 (80%) patients showed a complete remission, 4/20(20%) showed partial response, none of the patients were non-responders. All of the patients (20) who were taking corticosteroids were able to stop it by week 22 during infliximab treatment, and all showed a reduction in extraocular manifestations of Behçet's disease. None of the patients had worsening VA or new onset ocular complications.

Conclusions: Infliximab seems to be a useful alternative therapy for patients with sight-threatening uveitis unresponsive to the standard immunosuppressive therapy. Although infliximab can be used as first-line medications in bilateral OBD, unilateral case with visual acuity below (6/60) may also need initial infliximab infusion as the first-line drug. Azathioprine can be used as a long-term therapy to control recurrent attacks upon first suppression of ocular inflammation by biologicals. Infliximab is also effective treatment in ocular Behcet disease regarding long term therapy.

Key Words: Anti-tumor necrosis factor, Behcet's disease uveitis.

#### Acknowledgement

First of all, I wish to express my greatest thanks to ALLAH The most beneficent and merciful, for giving me the will and strength to fulfill this work.

I want to express my profound and sincere gratitude to Prof. Dr. Ayman Kamal El-Garf Professor of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, for his endless patience, the time provided for this work his kind and supervision of this work.

My deepest thanks and gratitude to Prof. Dr. Amira Abd El Sabour, Professor of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University,, for her remarkable ideas and remarks, for her time and effort in the supervision of this work and for her valuable cooperation in this thesis.

All the respect and gratitude to Prof. Dr. Mohamed Reda Awad Professor of Rheumatology and Rehabilitation, Faculty of Medicine, El Azhar University, for his greatest help and concern.

My sincere gratitude to Dr. Mohamed Abd Elazzem Consultant Ophthalmologist for his encouragement, valuable comments and support throughout the whole work.

I would like also to thank all my colleagues for their continuous help and support.

## **CONTENTS**

	Page
List of Abbreviations	I
List of Tables	II
List of Figures	III
Introduction & Aim of the Work	1
Review of Literature	
Chapter (1):	5
Ocular Manifestations of Behçet's Disease	
Chapter (2):	17
Immunopathogenesis of Behçet's Uveitis	
Chapter (3):	35
Biologics in the Treatment of Behçet's Uveitis	
Patients & Methods	60
Results	65
Discussion	89
Summary	103
References	106
Arabic Summary	

# **List of Abbreviations**

adhesion molecules (ICAM-1 and VCAM-1)
antigen-presenting cells (APCs)
Anti-IL-17 (AIN457)
Antinuclear antibodies (ANA)
Aqueous humor (AH)
Azathioprine (AZA),
Behçet's disease (BD)
Chronic infantile neurological cutaneous articular syndrome (CINCA)
Complete remission (CR)
Corticosteroids (CS)
Cyclosporine (CsA),
Cystoid macular edema (CME)
Cytotoxic combination therapy group (CCTG)
Experimental autoimmune uveo- retinitis (EAU)
Follicular helper T (TFH)
Fundus fluorescein angiography (FFA)
Helper T-cell (Th cell)
High-dose (HD)
Immunoglobulin G1 (IgG1)
Indocyanine green angiography (ICGA)
Induced regulatory T(iTreg) Infliximab (IFX)
Isoniazide (INH)
Interferon gamma (IFN-gamma)
Interleukin-2 (IL-2)
International Study Group (ISG)
Lipopolysaccharides (LPS)
Low-dose (LD)
Matrix metalloproteinases (MMPs)
Mitomycin C (MMC)
Moderate-dose (MD)
Natural killer (NK)
Natural regulatory T (nTreg)
Nitric oxide (NO)
Ocular Behçet's disease (OBD)
Optical coherence tomography (OCT)
Oral ulcers (OU)
Partial remission (PR)
Periphral blood mononuclear cells (PBMCs)
Plasmacytoid dendritic cells (PDC)

Plasmacytoid dendritic cells (PDC)
Posterior uveitis (PU)
Regulatory T-cells (Tregs)
Retinal vasculitis (RV)
Retinoic acid-related orphan receptor-gamma t (ROR-gamma t)
Rituximab group (RG)
SOLUBLE FasL (sFasL)
SOLUBLE TNF-α (sTNF-α)
THP precursor Th cell
Transforming growth factor (TGF)
Transmembrane TNF-α ( tTNF- α )
Tuberculosis {TB}
Tumor necrosis factor alpha(TNF-alpha)
Tumor necrosis factor receptor 1 (TNFR1)
Tumor necrosis factor receptor 2 (TNFR2)
Ultrasound biomicroscopy (UBM)
VASCULAR Endothelial Growth Factor (VEGF)
VISUAL acuity (VA)
VITROUS humor (vh)
VOGT-Koyanagi-Harada (VKH)

# **List of Figures**

Figures		Pages
1	eye anatomy	6
2	Retinal vasculitis with intraretinal hemorrhages	9
3	Optic disc neovascularization. B) Leakage from new	10
	optic disc vessels on fundus fluorescein angiography.	
4	End-stage ocular Behcet's disease.	11
5	Staining of vessel walls and leakage from inflamed	13
	vessels on fundus fluorescein angiography	
6	Leakage of fluorescein and cystoid macular edema.	14
7	. Helper T-cell (Th) activation and differentiation.	20
8	. Primary polarization of diverse CD4+ T cell subsets	22
9	Specific autoimmune response leading to inflammation	37
10	Stimulation of TNF-α receptor	39
11	Binding of therapeutic anti-TNF antibodies:	40
12	Infliximab molecule	42
13	Adalimumab Molecule	46
14	Effect of tocilizumab (anti-IL-6R).	49
15	Antigen presentation and T helper cell types	53
16	Rituximab and B cells	58
17	Pattern of uveitis	71
18	Infliximab treatment effects on VA after week 8,	73
	week 32 and week 56 compared to VA before	
	Infliximab initiation	
19	Results of IFX therapy on remission by the end of	75
	week 8	
20	Relapse subjects after week 8	76
21	Results of IFX therapy by the end of week 32	77

Figures		Pages
22	Relapse subjects after week 32	78
23	Results of IFX therapy by the end of follow up	79
24	Comparison of general features of group A and group	81
	B.	
25	Pattern of uveiitis in group A and in group B	83
26	General features of patients without relapse (group C)	85
	and patients with relapse (group D).	

# **List of Tables**

Tables		Pages
1	International Study Group for Behcet's Disease diagnostic criteria	61
2	The general characteristics of all patients	66
3	The disease manifestations of all patients	67
4	The thrombotic events in all patients.	67
5	Drug intake and Ocular complications before IFX therapy	69
6	The adverse effects of the conventional therapy.	70
7	Pattern of uveiitis in all patients.	70
8	Comparison between VA before Infliximab therapy and VA at week 8, week 32 and week 56 after IFX initiation	72
9	VA of the Right eyes in the beginning, after 8 weeks, 32weeks and 56 weeks of treatmen	73
10	VA of the Left eyes in the beginning, after 8 weeks, 32weeks and 56 weeks of treatmen	74
11	Results of IFX therapy on remission by the end of week 8	74
12	Relapse subject after week 8	75
13	Results of IFX therapy by the end of week 32	76
14	Relapse subjects after week 32	78
15	Results of IFX therapy by the end of follow up ( 56 weeks)	79
16	Comparison between general features of group A and group B	80
17	The disease manifestations in group A and in group B	81
18	The thrombotic events in group A and B	82
19	Pattern of uveiitis in group A and in group B	82

Tables		Pages
20	Comparison between patients without relapse (group C) and patients with relapse (group D) regarding age and disease duration	84
21	Comparison between the disease manifestations in group C and in group D	85
22	The thrombotic events in group C and D	86
23	Comparison between pattern of uveiitis in group C and in group D	87
24	Improvement of ocular complications during IFX therapy	87

#### Introduction

Ocular Behcet disease (OBD) is an idiopathic, immune disorder that produces unpredictable outbreaks of aggressive and exaggerated ocular inflammations. It clinically presents as episodic and recurrent hypopyon iridocyclitis along with vitreitis, retinitis, occlusive panuveitic vasculitis, and cystoid macular edema (CME), alternating with periods of inactive phases. Complications such as band keratopathy, glaucoma, vitreoretinal hemorrhage or detachment, macular degeneration, epiretinal membrane, vein occlusion may be encountered (*Evereklioglu*, 2005).

OBD comes in bursts and typically affects young adults in their most productive ages between 20 and 40 years with pediatric cases (*Borlu et al.*, 2006). However, its pathogenesis is still unclear and there is no laboratory screening profile to recognize and confirm disease activity (*Turko*" *et al.*, 2005). But still, recent investigations reveal some new insights into the cause in a genetic basis (*Borlu et al.*, 2009).

Behcet symptoms occur wherever there is a patch of inflammation. Therefore, it affects almost all tissue or organ in the body without exception. In its full spectrum, some prefer to call this disorder as "oculo-articulo-oromucocutaneous syndrome (Evereklioglu., 2011).

Infliximab is a chimeric (mouse/human) monoclonal antibody to tumor necrosis factor  $\alpha$  that binds to TNF- $\alpha$  and prevents it from binding to its receptor (*Taylor*, *2010*). Evidence suggests increased levels of TNF- $\alpha$  in serum and aqueous fluid in patients with intraocular inflammation due to Behçet's disease (*Evereklioglu.*, *2002*).

It is not altogether surprising, then, that TNF- $\alpha$  inhibitors have been effective in the management of uveitis in these patients. The first clinical evidence for this in the literature came in the form of a case series by *Sfikakis et al.*, (2001) who treated five patients with relapsing BD panuveitis with infliximab; they achieved remission within 24 hours of the first infusion and complete suppression by 7 days in all 5 patients (including no anterior chamber cell, no vasculitis, and no retinal lesions in any patient).

A report the following year described remission lasting up to 8 weeks after a series of 4 infusions in one patient (*Triolo et al.*, 2002). An interventional case series using a total of 3 infliximab infusions (at weeks 0, 2, and 6) to treat posterior uveitis in 5 patients with previous treatment failures included 3 patients with BD, all of whom demonstrated improved visual acuity in both eyes following treatment and essentially complete remission of ocular disease. Although patients were given additional infusions as needed, some experienced treatment-free remissions of up to 5 months (*Joseph et al.*, 2003).

The first report of longer-term use of infliximab for BD uveitis described a patient who had active disease despite cyclosporine A, azathioprine, and prednisolone and then had rapid resolution of inflammation on infliximab. With ongoing infusions every 8 weeks he was able to gradually taper and discontinue all other immunosuppressive medications (over the course of 14 months) and had no disease activity during the 16 months he was monitored; the final two months were under infliximab monotherapy (*Katsiari et al., 2001*).

# Introduction & Aim of the Work

Encouraged by the early successful case reports, other groups began treating difficult cases of Behçet's uveitis with infliximab and the number of case reports and series increased exponentially.

## **Aim of the Work**

Assess the efficacy and safety of Infliximab therapy in treatment of ocular manifestations in patients with Behcet's disease.



#### **Ocular Manifestations of Behçet's Disease**

Behçet's disease (BD), first described by *Hulusi Behçet in (1937)* is a chronic multisystem disorder characterized by recurrent episodes of uveitis, oral aphthous lesions, genital ulcers, and skin lesions, with underlying vasculitis *(Tugal et al., 2004)*.

Although the most frequent initial manifestations are oral and genital ulcerations, the majority of patients present with more severe ocular, joint, gastrointestinal system, vascular system, or central nervous system involvement (*Kansu et al., 2005*).

There is no pathognomonic finding or test for BD, and thus the diagnosis remains primarily clinical. Various sets of diagnostic criteria for BD have been suggested, and the criteria of the Japanese BD Research Committee and the 1990 classification of the International Study Group for BD are widely employed.

BD affects males more than females (2–10:1) along the silk route that extends from Mediterranean regions to Japan, where the disease is seen more commonly than in other areas. However, the male: female ratio is reversed in Western Europe and the US. The estimated prevalence of BD is between one in 10 000 and one in 1000 in the Mediterranean, the Middle East, and the Far East, with the highest prevalence being in Turkey where there are 80–300 cases per 100 000 population (*Everekliglu*, 2005).